Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKNASDAQ:CRBPNASDAQ:CUENASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.32-0.4%$0.30$0.22▼$1.56$28.87M0.621.09 million shs959,172 shsCRBPCorbus Pharmaceuticals$4.77-8.4%$7.80$4.76▼$61.90$58.65M3.12365,239 shs16,807 shsCUECue Biopharma$0.78-1.3%$1.19$0.45▼$2.26$49.41M1.88443,690 shs17,327 shsORMPOramed Pharmaceuticals$2.18-0.9%$2.29$1.96▼$3.09$87.92M1.61156,714 shs57,667 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos+48.06%+39.21%+19.00%-74.09%-74.09%CRBPCorbus Pharmaceuticals+3.38%-12.16%-25.29%-56.81%-86.12%CUECue Biopharma+5.35%-20.55%-34.16%-27.51%-56.59%ORMPOramed Pharmaceuticals+3.29%-6.78%+10.00%-8.71%-21.43%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos4.5116 of 5 stars3.15.00.04.71.82.51.3CRBPCorbus Pharmaceuticals3.5417 of 5 stars3.61.00.04.71.91.70.0CUECue Biopharma4.5306 of 5 stars3.55.00.04.72.50.81.3ORMPOramed Pharmaceuticals1.6498 of 5 stars0.03.00.00.03.20.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.20Hold$2.00525.00% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$59.131,140.82% UpsideCUECue Biopharma 3.00Buy$4.75508.97% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CRBP, ALLK, ORMP, and CUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025CRBPCorbus PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$51.003/12/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $50.003/11/2025CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$70.00 ➝ $53.002/28/2025CRBPCorbus PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/18/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.002/10/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $75.001/27/2025ALLKAllakosPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold1/27/2025ALLKAllakosCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/A($1.56) per shareN/ACUECue Biopharma$9.53M5.18N/AN/A$0.82 per share0.95ORMPOramed Pharmaceuticals$1.34M65.61N/AN/A$4.04 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%5/8/2025 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$3.66N/AN/AN/AN/A-42.28%-32.92%5/6/2025 (Estimated)CUECue Biopharma-$50.73M-$0.90N/AN/AN/A-468.02%-156.38%-88.07%4/14/2025 (Estimated)ORMPOramed Pharmaceuticals$5.53M-$0.2119.83N/AN/AN/A-7.27%-6.20%5/8/2025 (Estimated)Latest CRBP, ALLK, ORMP, and CUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/14/2025N/ACUECue Biopharma-$0.17N/AN/AN/A$1.70 millionN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A3/11/2025Q4 2024CRBPCorbus Pharmaceuticals-$1.02-$0.78+$0.24-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08CRBPCorbus PharmaceuticalsN/A13.8413.84CUECue Biopharma0.052.222.22ORMPOramed PharmaceuticalsN/A27.0827.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%CRBPCorbus Pharmaceuticals64.64%CUECue Biopharma35.04%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%CRBPCorbus Pharmaceuticals4.00%CUECue Biopharma12.26%ORMPOramed Pharmaceuticals13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.20 million74.94 millionOptionableCRBPCorbus Pharmaceuticals4012.23 million11.69 millionOptionableCUECue Biopharma6063.35 million55.58 millionOptionableORMPOramed Pharmaceuticals1040.31 million34.79 millionOptionableCRBP, ALLK, ORMP, and CUE HeadlinesRecent News About These CompaniesOramed Pharmaceuticals (NASDAQ:ORMP) Announces Quarterly Earnings ResultsMarch 29, 2025 | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?March 26, 2025 | marketbeat.comHead-To-Head Analysis: Pharmaxis (OTCMKTS:PXSLY) & Oramed Pharmaceuticals (NASDAQ:ORMP)March 25, 2025 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?March 18, 2025 | marketbeat.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLCMarch 8, 2025 | marketbeat.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comCongressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals StockFebruary 27, 2025 | benzinga.comOramed Pharmaceuticals to Spin Off Its Protein Oral Delivery TechnologyFebruary 11, 2025 | contractpharma.comOraTech to pioneer oral insulin with $75 million investmentFebruary 11, 2025 | msn.comOramed enters JV for insulin development and commercializationFebruary 11, 2025 | markets.businessinsider.comOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinFebruary 11, 2025 | prnewswire.comScilex announces early installment payment on senior secured promissory noteDecember 16, 2024 | markets.businessinsider.comORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsDecember 2, 2024 | finance.yahoo.comOramed Pharm (ORMP) Receives a Hold from H.C. WainwrightSeptember 9, 2024 | markets.businessinsider.comORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, BuybacksAugust 30, 2024 | finance.yahoo.comOramed Pharmaceuticals sees highest patent filings and grants during April in Q2 2024July 22, 2024 | pharmaceutical-technology.com3 Micro-Cap Moonshots for Fearless InvestorsJuly 8, 2024 | investorplace.comOramed Letter to ShareholdersJune 26, 2024 | prnewswire.comOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockJune 26, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, ALLK, ORMP, and CUE Company DescriptionsAllakos NASDAQ:ALLK$0.32 0.00 (-0.40%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Corbus Pharmaceuticals NASDAQ:CRBP$4.76 -0.44 (-8.37%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Cue Biopharma NASDAQ:CUE$0.78 -0.01 (-1.28%) As of 10:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Oramed Pharmaceuticals NASDAQ:ORMP$2.18 -0.02 (-0.86%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
